Simultaneous Determination of a Novel PD-L1 Inhibitor, IMMH-010, and Its Active Metabolite, YPD-29B, in Rat Biological Matrices by Polarity-Switching Liquid Chromatography-Tandem Mass Spectrometry: Application to ADME Studies

• Hauptverfasser: Jianwei Jiang (Verfasst von), Xiaowen Zou (Verfasst von), Yuke Liu (Verfasst von), Xiao Liu (Verfasst von), Kai Dong (Verfasst von), Xiaoqing Yao (Verfasst von), Zhiqiang Feng (Verfasst von), Xiaoguang Chen (Verfasst von), Li Sheng (Verfasst von), Yan Li (Verfasst von)
• Format: Buch
• Veröffentlicht: Frontiers Media S.A., 2021-06-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

IMMH-010 is a prodrug of YPD-29B, which is a novel PD-L1 inhibitor. A specific and sensitive LC-MS/MS method with polarity switching was developed and validated for the simultaneous determination of IMMH-010 and YPD-29B in rat plasma, liver, brain, urine and fecal samples. Method validation was inve...